0
Original Contributions |

Corticomotoneuronal Integrity and Adaptation in Spinal Muscular Atrophy

Michelle A. Farrar, MBBS, FRACP; Steve Vucic, PhD, FRACP; Heather M. Johnston, MBChB, FRACP; Matthew C. Kiernan, DSc, FRACP
Arch Neurol. 2012;69(4):467-473. doi:10.1001/archneurol.2011.1697.
Text Size: A A A
Published online

Objective  To gain further insight into disease pathophysiologic process and potential adaptations through investigating whether cortical dysfunction or plasticity is a feature of spinal muscle atrophy (SMA).

Design  Prospective, double-center study.

Setting  Outpatient clinics and research institute.

Participants  Clinical assessments, combined with threshold-tracking transcranial magnetic stimulation techniques, were completed in 11 genetically characterized patients with SMA.

Main Outcome Measures  Clinical, functional, and neurophysiologic variables were compared between the 11 patients with SMA types 2 and 3, 24 healthy control participants, and 81 patients with amyotrophic lateral sclerosis (ALS) serving as disease controls.

Results  Maximal motor-evoked potential amplitude as a percentage of the compound muscle action potential was significantly increased in patients with SMA compared with the healthy controls but was similar to that in ALS (SMA, mean [SE], 39.7% [4.0%]; ALS, 38.8% [2.8%]; controls, 20.3% [2.5%]; F = 10.1; P < .001). In contrast, short-interval intracortical inhibition (SMA, 14.4% [1.6%]; ALS, 4.3% [1.8%]; controls, 17.0% [2.3%]; F = 11.4; P < .001) and cortical silent-period duration (SMA, 204.4 [9.8] milliseconds; ALS, 182.7 [5.2] milliseconds; controls, 208.8 [3.7] milliseconds; F = 4.8; P = .01), similar between SMA patients and healthy controls, were significantly larger when compared with the findings in ALS. Of relevance, peripheral disease burden as measured by the compound muscle action potential amplitude (SMA, 6.3 [0.8] mV; ALS, 5.9 [0.4] mV; controls, 11.8 [0.5] mV; F = 35.5; P < .001) and Neurophysiological Index (SMA, 0.7 [0.2]; ALS, 0.7 [0.1]; controls, 3.1 [0.2]; F = 108.2; P < .001), were significantly reduced in both SMA and ALS patients when compared with healthy controls.

Conclusions  Taken together, findings from the present study suggest that despite spinal motoneuron degeneration there remains preservation of corticomotoneuronal function in SMA. The greater corticomotoneuronal projections to surviving spinal motoneurons likely represent an adaptive response to spinal motoneuron degeneration in SMA.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Place holder to copy figure label and caption
Grahic Jump Location

Figure 1. Comparison of compound muscle action potential (CMAP) amplitude and Neurophysiological Index values between the 3 study groups. A, The CMAP amplitude was significantly reduced in patients with spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) vs healthy control participants but comparable between the SMA and ALS groups. B, The Neurophysiological Index value was reduced in patients with SMA and ALS vs healthy controls but comparable between the SMA and ALS groups. * P < .001. Limit lines indicate standard error.

Place holder to copy figure label and caption
Grahic Jump Location

Figure 2. The maximum motor-evoked potential (MEP) obtained during transcranial magnetic stimulation was expressed as a percentage of the compound muscle action potential (CMAP) amplitude recorded following electrical stimulation to determine the corticomotoneuronal contribution. The MEP:CMAP ratio was significantly increased in patients with spinal muscular atrophy (SMA) and those with amyotrophic lateral sclerosis (ALS) vs healthy control participants. * P < .001. Limit lines indicate standard error.

Place holder to copy figure label and caption
Grahic Jump Location

Figure 3. Short-interval intracortical inhibition (SICI). In healthy control participants, SICI occurs between interstimulus intervals (ISIs) of 1 to 7 milliseconds. This is followed by intracortical facilitation (ICF), as indicated by a decrease in the test stimulus intensity. A, The SICI was comparable between patients with spinal muscular atrophy (SMA) and the healthy controls and significantly reduced in patients with amyotrophic lateral sclerosis (ALS) (* P = .001). B, The mean SICI, between ISIs 1 to 7 milliseconds, in patients with SMA was similar to that of controls but significantly greater vs patients with ALS (P = .001). C, The ICF was similar between patients with SMA and healthy controls but significantly smaller compared with patients with ALS († P = .02). Limit lines indicate standard error.

Place holder to copy figure label and caption
Grahic Jump Location

Figure 4. Correlation studies illustrating a relationship between clinical and peripheral neurophysiologic measures of disease severity in patients with spinal muscular atrophy, namely, compound muscle action potential (CMAP) amplitude. A, Medical Research Council (MRC) sum score. B, Spinal Muscular Atrophy Functional Rating Scale (SMAFRS). The solid lines represent the linear regression fit across all subjects. Spearman rank correlation coefficients and Bonferroni-corrected P values are shown.

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
Jobs